SG10201500274TA - Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists - Google Patents

Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Info

Publication number
SG10201500274TA
SG10201500274TA SG10201500274TA SG10201500274TA SG10201500274TA SG 10201500274T A SG10201500274T A SG 10201500274TA SG 10201500274T A SG10201500274T A SG 10201500274TA SG 10201500274T A SG10201500274T A SG 10201500274TA SG 10201500274T A SG10201500274T A SG 10201500274TA
Authority
SG
Singapore
Prior art keywords
antagonists
variable domains
antibody variable
stable anti
tnfr1 polypeptides
Prior art date
Application number
SG10201500274TA
Inventor
Silva Inusha De
Armin Sepp
Adriaan Allart Stoop
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201500274T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SG10201500274TA publication Critical patent/SG10201500274TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SG10201500274TA 2009-10-27 2010-10-25 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists SG10201500274TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25523509P 2009-10-27 2009-10-27

Publications (1)

Publication Number Publication Date
SG10201500274TA true SG10201500274TA (en) 2015-03-30

Family

ID=43382391

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201500274TA SG10201500274TA (en) 2009-10-27 2010-10-25 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Country Status (26)

Country Link
US (1) US20150210767A1 (en)
EP (1) EP2493504B1 (en)
JP (1) JP2013507978A (en)
KR (1) KR20120101417A (en)
CN (1) CN102686239B (en)
AR (1) AR078763A1 (en)
AU (1) AU2010311640B2 (en)
BR (1) BR112012010114A2 (en)
CA (1) CA2777312A1 (en)
CL (1) CL2012001055A1 (en)
CO (1) CO6612254A2 (en)
CR (1) CR20120197A (en)
DO (1) DOP2012000113A (en)
EA (1) EA022898B1 (en)
ES (1) ES2552177T3 (en)
IL (1) IL218860A0 (en)
MA (1) MA33758B1 (en)
MX (1) MX2012005024A (en)
NZ (1) NZ599114A (en)
PE (1) PE20121564A1 (en)
SG (1) SG10201500274TA (en)
TW (1) TW201125877A (en)
UA (1) UA107200C2 (en)
UY (1) UY32969A (en)
WO (1) WO2011051217A1 (en)
ZA (1) ZA201203052B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022925B1 (en) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
EP2721066A1 (en) * 2011-06-17 2014-04-23 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
CA2897345A1 (en) * 2013-01-31 2014-08-07 Glaxo Group Limited Method of producing a protein
WO2015104322A1 (en) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
SG11201808680RA (en) * 2016-04-05 2018-11-29 Univ Stuttgart MONOVALENT INHIBITOR OF huTNFR1 INTERACTION
JP2023541816A (en) 2020-08-27 2023-10-04 イノージ・セラピューティクス・コーポレイション Methods and compositions for treating autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN114699533B (en) * 2022-05-06 2023-05-09 郑州大学 Preparation method and application of nucleic acid aptamer and polypeptide crosslinked double-target composite nucleic acid nano-drug

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc CHANGED ANTIBODIES.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
DE768377T1 (en) 1988-09-02 1998-01-02 Dyax Corp Production and selection of recombinant proteins with different binding sites
ATE92107T1 (en) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
GB2342094B (en) 1997-07-07 2002-10-23 Medical Res Council In vitro sorting method
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
DK1399484T3 (en) 2001-06-28 2010-11-08 Domantis Ltd Double-specific ligand and its use
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
PT1517921E (en) 2002-06-28 2006-09-29 Domantis Ltd DIFFERENTLY SPECIFIED LIGANDS WITH SEMI-LIFE IN THE INCREASED SERUM
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
JP2006520584A (en) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． Stabilized single domain antibody
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
JP2006523090A (en) 2002-12-27 2006-10-12 ドマンティス リミテッド Bispecific single domain antibody specific for ligand and for ligand receptor
AU2004239065B2 (en) 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
SI1639011T1 (en) 2003-06-30 2009-04-30 Domantis Ltd Pegylated single domain antibodies (dAb)
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
CN101084014A (en) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 Single domain antibodies against tnfr1 and methods of use therefor
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
KR20100018040A (en) 2007-06-06 2010-02-16 도만티스 리미티드 Methods for selecting protease resistant polypeptides
JP5759391B2 (en) * 2009-02-19 2015-08-05 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Improved antiserum albumin binding mutant
EA022925B1 (en) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists

Also Published As

Publication number Publication date
EA201290172A1 (en) 2013-04-30
TW201125877A (en) 2011-08-01
PE20121564A1 (en) 2012-11-29
JP2013507978A (en) 2013-03-07
WO2011051217A1 (en) 2011-05-05
CR20120197A (en) 2012-06-22
CA2777312A1 (en) 2011-05-05
ZA201203052B (en) 2013-09-25
US20150210767A1 (en) 2015-07-30
UY32969A (en) 2011-05-31
CL2012001055A1 (en) 2012-10-05
EP2493504A1 (en) 2012-09-05
ES2552177T3 (en) 2015-11-26
BR112012010114A2 (en) 2017-08-08
CN102686239B (en) 2016-02-03
AU2010311640B2 (en) 2015-01-29
UA107200C2 (en) 2014-12-10
CN102686239A (en) 2012-09-19
KR20120101417A (en) 2012-09-13
IL218860A0 (en) 2012-06-28
DOP2012000113A (en) 2012-08-15
CO6612254A2 (en) 2013-02-01
MX2012005024A (en) 2012-09-07
EA022898B1 (en) 2016-03-31
NZ599114A (en) 2014-09-26
AR078763A1 (en) 2011-11-30
MA33758B1 (en) 2012-11-01
EP2493504B1 (en) 2015-10-07
AU2010311640A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
IL214648A0 (en) Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
HK1138022A1 (en) Polypeptides, antibody variable domains & antagonists
IL201399A0 (en) Polypeptides, antibody variable domains and antagonists
IL218860A0 (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
IL252561A0 (en) Anti-siglec-15 antibodies, polynucleotides encoding the same, compositions comprising the same and uses thereof
IL232009A (en) Isolated, alpha4beta7 heterodimer specific antigen binding protein and various aspects related thereto
HK1147269A1 (en) Anti-vegf antibodies vegf
ZA201008993B (en) Anti-human interleukin-20 antibodies
EP2304440A4 (en) Novel monoclonal antibodies against hpv proteins
ZA201105323B (en) Agonists and antagonists of the sip5 receptor,and methods of uses thereof
EP2331579A4 (en) Monoclonal antibodies
ZA201103588B (en) Polypeptides,antibody variable domains & antagonists
IL218296A0 (en) Obpgplys/endolysin polypeptides, fusion proteins and compositions compriisng the same and uses thereof
GB0708002D0 (en) Antibodies
IL236236A (en) Fam26f polypeptide antibodies
AP2012006276A0 (en) New CCR2 receptor antagonists and uses thereof.
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2354161A4 (en) Anti-nr10 antibody, and use thereof
GB0811298D0 (en) Characterising polypeptides
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
EP2322562A4 (en) Monoclonal antibody, and immunoassay using same
GB0718737D0 (en) Antibodies
ZA201001260B (en) Immunogenic polypeptides and monoclonal antibodies
EP2399934A4 (en) Novel monoclonal antibody, and use thereof
SI2354161T1 (en) Anti-nr10 antibody, and use thereof